重大事件
即時報告
8-K
2026-06-18
BioCardia 發佈股東公開信 更新業務策略與發展機會
AI 繁中摘要
BioCardia, Inc.（納斯達克代號：BCDA）於2026年6月18日提交8-K申報，主要內容為發佈一封致股東的公開信，更新公司業務策略、首要任務及業務發展機會。📄
該份8-K屬於規管FD披露（Item 7.01），未有提供具體財務業績數字或季度盈餘數據。新聞稿全文已作為附件99.1隨申報提交，但未被視為「已存檔」文件，亦不承擔《證券交易法》第18條下的法律責任。
管理層在信中闡述了公司當前的戰略重點與未來發展方向，惟詳細內容需參閱原文附件。對投資者而言，此舉反映BioCardia正積極與股東溝通業務轉型或擴張計劃，可能預示未來融資、合作或管線進展。鑑於8-K通常涉及重大事件，投資者應關注後續公告，以評估其對股價及公司基本面的潛在影響。📊
（註：本摘要僅基於8-K表格披露之事實，未包含新聞稿具體內容，建議查閱完整信函以獲取詳細策略資訊。）
展開英文正文
bcda20260617_8k.htm false 0000925741 0000925741 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2026 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 320 Soquel Way Sunnyvale, California 94085 (Address of principal executive offices and zip code) Registrant’s telephone number, including area code: (650) 226-0120 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 BCDA The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter) ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 7.01 Regulation FD Disclosure. On June 18, 2026, BioCardia, Inc. issued a press release containing its letter to shareholders, which provides an update on the Company’s business strategy, top priorities, and business development opportunities. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K. The information furnished pursuant to this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 104 BioCardia, Inc. press release dated June 18, 2026 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: June 18, 2026